This is the authors' abstract. We don't add key points for this paper.
Patients with fistulizing Crohn's disease who have a response to induction therapy with infliximab have an increased likelihood of a sustained response over a 54-week period if infliximab treatment is continued every 8 weeks.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Sands et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: